EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Eldecalcitol and calcium supplementation in Chinese women with postmenopausal osteoporosis: a prospective observational cohort study

Yan Jiang, Yuhong Zeng, Li Xin, Wei Chen, Youjia Xu, Shoujin Tian, Qinglai Wang, Jianjun Li, Shihong Chen, Xuanxia Lin, Qifeng Ying, Shun Chiba und 5 weitere

Journal of Bone and Mineral Metabolism · 2026-09 · 44 (5) · 597-609

DOI: 10.1007/s00774-026-01735-x ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Bone and Mineral Metabolism, online erschienen am 16.06.2026. Verfasst von Yan Jiang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Peking Union Medical College Hospital, No.1 Shuai-Fu-Yuan, Beijing, 100730, China. Hauptthemen laut MEDLINE: Calcium, Dietary Supplements, Osteoporosis, Postmenopausal, Vitamin D. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Eldecalcitol is an active vitamin D 3 derivative approved for the treatment of osteoporosis in Japan and postmenopausal osteoporosis in China. However, the impact of concomitant calcium supplementation on its safety profile is unclear. Materials and methods This was a prospective, observational, non-interventional post-marketing drug intensive monitoring study in Chinese postmenopausal women with osteoporosis (NCT05433207). Data were collected using an electronic case report form at baseline, before initial eldecalcitol dosing, and during routine clinical visits over a 1-year follow-up period.

Results

One thousand patients were enrolled from 29 Chinese clinical sites; 958 received eldecalcitol (853 without/105 with calcium supplementation). The mean age (standard deviation [SD]) of patients was 65.6 (9.0) years and mean (SD) time since osteoporosis diagnosis was 2.7 (3.8) years. Adverse drug reactions (ADRs) affected 39.2% and 42.9% of patients in the without and with calcium supplementation groups, respectively. 22 (2.3%) patients developed hypercalcemia including 17 (1.99%) and 5 (4.76%) in the without and with calcium supplementation groups, respectively. Multivariable logistic regression analyses indicated that those receiving calcium were more likely to experience hypercalcemia (adjusted odds ratio [OR] 3.07, 95% confidence interval [CI] 1.16, 8.10, P = 0.02) than those not receiving calcium. ADRs of urolithiasis were experienced by three patients (0.35%) in the without calcium supplementation group.

Conclusion

This study confirmed the real-world safety profile of eldecalcitol in a large population of Chinese women with postmenopausal osteoporosis. Hypercalcemia incidence was higher in patients with compared to without calcium supplementation, indicating that concomitant eldecalcitol and calcium should be carefully considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CalciumDietary SupplementsOsteoporosis, PostmenopausalVitamin DAgedFemaleHumansMiddle AgedChinaHypercalcemiaProspective StudiesProduct Surveillance, PostmarketingEast Asian People

Stichwörter der Autor:innen

Adverse drug reactionsEldecalcitolHypercalcemiaOsteoporosis

Substanzen

CalciumeldecalcitolVitamin D

Autor:innen und Institutionen

  • Peking Union Medical College Hospital, No.1 Shuai-Fu-Yuan, Beijing, 100730, China.
  • Xi'an Hong Hui Hospital, No.555 East Youyi Road Nanshao Gate anguo Road No.76, Xi'an, 710054, Shanxi, China.
  • The Affiliated Hospital of Xuzhou Medical University, No.99 West Huaihai Road, Xuzhou, 221006, Jiangsu, China.
  • Xinyi Hospital of Traditional Chinese Medicine, No.168 Daqiao Dong Lu, Xinyi, 221416, Jiangsu, China.
  • The Second Affiliated Hospital of Soochow University, No.1055 Sanxiang Road Gusu District, Suzhou, 215004, Jiangsu, China.
  • Zhangjiagang First People's Hospital, No.68, Jiyang West Road, Zhangjiagang, 215638, Jiangsu, China.

Zitieren

APA

Jiang, Y., Zeng, Y., Xin, L., Chen, W., Xu, Y., Tian, S., Wang, Q., Li, J., Chen, S., Lin, X., Ying, Q., Chiba, S., Yamagiwa, C., Yamaguchi, T., Ke, Z., Xia, W., & Takeuchi, Y. (2026). Eldecalcitol and calcium supplementation in Chinese women with postmenopausal osteoporosis: a prospective observational cohort study. Journal of Bone and Mineral Metabolism, 44(5), 597-609. https://doi.org/10.1007/s00774-026-01735-x

Vancouver

Jiang Y, Zeng Y, Xin L, Chen W, Xu Y, Tian S, et al. Eldecalcitol and calcium supplementation in Chinese women with postmenopausal osteoporosis: a prospective observational cohort study. Journal of Bone and Mineral Metabolism. 2026;44(5):597-609. doi:10.1007/s00774-026-01735-x

BibTeX
@article{Jiang2026,
  author = {Jiang, Yan and Zeng, Yuhong and Xin, Li and Chen, Wei and Xu, Youjia and Tian, Shoujin and Wang, Qinglai and Li, Jianjun and Chen, Shihong and Lin, Xuanxia and Ying, Qifeng and Chiba, Shun and Yamagiwa, Chiemi and Yamaguchi, Tomohiro and Ke, Zheng and Xia, Weibo and Takeuchi, Yasuhiro},
  title = {Eldecalcitol and calcium supplementation in Chinese women with postmenopausal osteoporosis: a prospective observational cohort study},
  journal = {Journal of Bone and Mineral Metabolism},
  year = {2026},
  volume = {44},
  number = {5},
  pages = {597--609},
  doi = {10.1007/s00774-026-01735-x}
}
Kostenlos starten →